Outcome | Rhodiola | Placebo | Odds ratio/difference | Adjusted |
---|---|---|---|---|
(N=102) | (N=102) | (95% CI) | P value | |
Primary endpoint | ||||
 AMSa | 62 (60.8) | 62 (60.8) | 1.02 (0.69, 1.52) ††| 0.90 |
Secondary endpoint | ||||
 Severe AMSb | 36 (35.3) | 30 (29.4) | 1.42 (0.90, 2.25) ††| 0.13 |
 Headache | 81 (79.4) | 78 (77.5) | 1.17 (0.75, 1.83) ††| 0.48 |
 Severe headachec | 33 (32.4) | 30 (29.4) | 1.16 (0.71, 1.89) ††| 0.55 |
 SpO2, %d | 88.6 ± 3.9 | 88.6 ± 4.3 | –0.13 (–0.93, 0.66) ‡‡ | 0.74 |
 ∆SpO2, % | 9.6 ± 3.8 | 9.5 ± 4.2 | 0.16 (–0.65, 0.97) ‡‡ | 0.70 |
 Pulse rate, /mine | 99.2 ± 14.6 | 99.8 ± 14.2 | –0.30 (–2.61, 2.02) ‡‡ | 0.80 |
Other clinical measures | ||||
 AMS symptoms scoref | ||||
  Headache | 1.17 ± 0.81 | 1.13 ± 0.83 | 0.05 (-0.10, 0.20) ‡‡ | 0.50 |
  Dizziness | 0.87 ± 0.82 | 0.79 ± 0.79 | 0.09 (-0.06, 0.25) ‡‡ | 0.29 |
  Weakness | 0.94 ± 0.81 | 0.99 ± 0.84 | –0.02 (–0.17, 0.13) ‡‡ | 0.81 |
  Vomiting | 0.52 ± 0.70 | 0.41 ± 0.62 | 0.12 (–0.01, 0.25) ‡‡ | 0.08 |
  Sleep | 1.45 ± 0.99 | 1.55 ± 0.96 | –0.07 (–0.29, 0.14) ‡‡ | 0.49 |
 LLS score | 3.84 ± 2.49 | 3.77 ± 2.54 | 0.19 (-0.27, 0.55) ‡‡ | 0.51 |